Abstrakt

Przypisy

• 1. Amu S., Gjertsson I., Brisslert M.: Functional characterization ofmurine CD25 expressing B cells. Scand. J. Immunol., 2010; 71: 275-282
  Google Scholar
• 2. Antosz H., Choroszyńska D.: Negative regulation of Toll-like receptorsignalling. Postępy Hig. Med. Dośw., 2013; 67: 339-350
  Google Scholar
• 3. Antosz H., Sajewicz J., Marzec-Kotarska B., Kocki J., DmoszyńskaA.: Different expression of CD180, CD284 and CD14 receptors on theCD19+ subpopulation of normal and B-CLL lymphocytes. Folia Histochem.Cytobiol., 2009; 47: 593-598
  Google Scholar
• 4. Arvaniti E., Ntoufa S., Papakonstantinou N., Touloumenidou T.,Laoutaris N., Anagnostopoulos A., Lamnissou K., Caligaris-CappioF., Stamatopoulos K., Ghia P., Muzio M., Belessi C.: Toll-like receptorsignaling pathway in chronic lymphocytic leukemia: distinct geneexpression profiles of potential pathogenic significance in specificsubsets of patients. Haematologica, 2011; 96: 1644-1652
  Google Scholar
• 5. Bertilaccio M.T., Simonetti G., Dagklis A., Rocchi M., RodriguezT.V., Apollonio B., Mantovani A., Ponzoni M., Ghia P., Garlanda C.,Caligaris-Cappio F., Muzio M.: Lack of TIR8/SIGIRR triggers progressionof chronic lymphocytic leukemia in mouse models. Blood,2011; 118: 660-669
  Google Scholar
• 6. Brisslert M., Bokarewa M., Larsson P., Wing K., Collins L.V., Tarkowski A.: Phenotypic and functional characterization of humanCD25+ B cells. Immunology, 2006; 117: 548-557
  Google Scholar
• 7. Chiron D., Bekeredjian-Ding I., Pellat-Deceunynck C., Bataille R.,Jego G.: Toll-like receptors: lessons to learn from normal and malignanthuman B cells. Blood, 2008; 112: 2205-2213
  Google Scholar
• 8. Damle R.N., Calissano C., Chiorazzi N.: Chronic lymphocytic leukaemia:a disease of activated monoclonal B cells. Best Pract. Res.Clin. Haematol., 2010; 23: 33-45
  Google Scholar
• 9. D’Arena G., Musto P., Nunziata G., Cascavilla N., Savino L., PistoleseG.: CD69 expression in B-cell chronic lymphocytic leukemia: a newprognostic marker? Haematologica, 2001; 86: 995-996
  Google Scholar
• 10. De Fanis U., Romano C., Dalla Mora L., Sellitto A., GuastafierroS., Tirelli A., Bresciano E., Giunta R., Lucivero G.: Differences inconstitutive and activation-induced expression of CD69 and CD95between normal and chronic lymphocytic leukemia B cells. Oncol.Rep., 2003; 10: 653-658
  Google Scholar
• 11. Dębińska A., Boznański A.: The role of Toll-like receptors in thepathogenesis of allergic diseases – where is the truth? Postępy Hig.Med. Dośw., 2014; 68: 230-237
  Google Scholar
• 12. Francis S., Karanth M., Pratt G., Starczynski J., Hooper L., FeganC., Pepper C., Valcarcel D., Milligan D.W., Delgado J.: The effect ofimmunoglobulin VH gene mutation status and other prognostic factorson the incidence of major infections in patients with chroniclymphocytic leukemia. Cancer, 2006; 107: 1023-1033
  Google Scholar
• 13. Ghamlouch H., Ouled-Haddou H., Damaj G., Royer B., Gubler B.,Marolleau J.P.: A combination of cytokines rescues highly purifiedleukemic CLL B-cells from spontaneous apoptosis in vitro. PLoS One,2013; 8: e60370
  Google Scholar
• 14. Grandjenette C., Kennel A., Faure G.C., Béné M.C., Feugier P.:Expression of functional toll-like receptors by B-chronic lymphocyticleukemia cells. Haematologica, 2007; 92: 1279-1281
  Google Scholar
• 15. Gray C., Ahmed M.S., Mubarak A., Kasbekar A.V., Derbyshire S.,McCormick M.S., Mughal M.K., McNamara P.S., Mitchell T., ZhangQ.: Activation of memory Th17 cells by domain 4 pneumolysin inhuman nasopharynx-associated lymphoid tissue and its associationwith pneumococcal carriage. Mucosal Immunol., 2014; 7: 705-717
  Google Scholar
• 16. Hallek M.: Chronic lymphocytic leukemia: 2013 update on diagnosis,risk stratification and treatment. Am. J. Hematol., 2013; 88:803-816
  Google Scholar
• 17. Hartmann G., Krieg A.M.: Mechanism and function of a newlyidentified CpG DNA motif in human primary B cells. J. Immunol.,2000; 164: 944-953
  Google Scholar
• 18. He B., Qiao X., Cerutti A.: CpG DNA induces IgG class switch DNArecombination by activating human B cells through an innate pathwaythat requires TLR9 and cooperates with IL-10. J. Immunol.,2004; 173: 4479-4491
  Google Scholar
• 19. Jahrsdorfer B., Mühlenhoff L., Blackwell S.E., Wagner M., PoeckH., Hartmann E., Jox R., Giese T., Emmerich B., Endres S., WeinerG.J., Hartmann G.: B-cell lymphomas differ in their responsivenessto CpG oligodeoxynucleotides. Clin. Cancer Res., 2005; 11: 1490-1499
  Google Scholar
• 20. Kamerling J.P.: Pneumococcal polysaccharide: a chemical view.In: Streptococcus pneumoniae: Molecular Biology and Mechanismsof Disease. Mary Ann Liebert, Inc. NY, USA, 2000: 81-114
  Google Scholar
• 21. Kaufmann T., Strasser A., Jost P.J.: Fas death receptor signalling:roles of Bid and XIAP. Cell Death Differ., 2012; 19: 42-50
  Google Scholar
• 22. Kowalczyk E., Siednienko J., Matuszyk J.: Regulation of Toll-likereceptors-dependent inflammatory response. Postępy Hig. Med.Dośw., 2013; 67: 201-213
  Google Scholar
• 23. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., TeasdaleR., Koretzky G.A., Klinman D.M.: CpG motifs in bacterial DNAtrigger direct B-cell activation. Nature, 1995; 374: 546-549
  Google Scholar
• 24. Linet M.S., Schubauer-Berigan M.K., Weisenburger D.D., Richardson D.B., Landgren O., Blair A., Silver S., Field R.W., CaldwellG., Hatch M., Dores G.M.: Chronic lymphocytic leukaemia: an overviewof aetiology in light of recent developments in classificationand pathogenesis. Br. J. Haematol., 2007; 139: 672-686
  Google Scholar
• 25. Luczaj-Cepowicz E., Marczuk-Kolada G., Zalewska A., PawińskaM., Leszczyńska K.: Antibacterial activity of selected glass ionomercements. Postępy Hig. Med. Dośw., 2014; 68: 23-28
  Google Scholar
• 26. Molica S.: Infections in chronic lymphocytic leukemia: risk factors,and impact on survival, and treatment. Leuk. Lymphoma, 1994;13: 203-214
  Google Scholar
• 27. Molica S., Mannella A., Dattilo A., Levato D., Iuliano F., Peta A.,Consarino C., Magro S.: Differential expression of BCL-2 oncoproteinand Fas antigen on normal peripheral blood and leukemic bonemarrow cells. A flow cytometric analysis. Haematologica, 1996; 81:302-309
  Google Scholar
• 28. Nosari A.: Infectious complications in chronic lymphocytic leukemia.Mediterr. J. Hematol. Infect. Dis., 2012; 4: e2012070
  Google Scholar
• 29. Oscier D., Fegan C., Hillmen P., Illidge T., Johnson S., MaguireP., Matutes E., Milligan D.: Guidelines Working Group of the UK CLLForum. British Committee for Standards in Haematology. Guidelineson the diagnosis and management of chronic lymphocytic leukaemia.Br. J. Haematol., 2004; 125: 294-317
  Google Scholar
• 30. Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N.,Pasternack B.S.: Clinical staging of chronic lymphocytic leukemia.Blood, 1975; 46: 219-234
  Google Scholar
• 31. Rossmann E.D., Lewin N., Jeddi-Tehrani M., Osterborg A., MellstedtH.: Intracellular T cell cytokines in patients with B cell chroniclymphocytic leukaemia (B-CLL). Eur. J. Haematol., 2002; 68: 299-306
  Google Scholar
• 32. Rozková D., Novotná L., Pytlik R., Hochová I., Kozák T., BartunkováJ., Spisek R.: Toll-like receptors on B-CLL cells: expression andfunctional consequences of their stimulation. Int. J. Cancer, 2010;126: 1132-1143
  Google Scholar
• 33. Sachanas S., Levidou G., Angelopoulou M.K., MoschogiannisM., Yiakoumis X., Kalpadakis C., Vassilakopoulos T.P., KontopidouF., Tsirkinidis P., Dimitrakopoulou A., Kokoris S., Dimitriadou E.,Kyrtsonis M.C., Panayiotidis P., Papadaki H., Patsouris E., KorkolopoulouP., Pangalis G.A.: Apoptotic and proliferative characteristicsof proliferation centers in lymph node sections of patients withchronic lymphocytic leukemia. Leuk. Lymphoma, 2014; 55: 571-582
  Google Scholar
• 34. Seda V., Mraz M.: B-cell receptor signalling and its crosstalkwith other pathways in normal and malignant cells. Eur. J. Haematol.,2015; 94: 193-205
  Google Scholar
• 35. Shvidel L., Tadmor T., Braester A., Bairey O., Rahimi-LeveneN., Herishanu Y., Klepfish A., Ruchlemer R., Berrebi A., Polliack A.,Israeli CLL Study Group: Serum immunoglobulin levels at diagnosishave no prognostic significance in stage A chronic lymphocyticleukemia: a study of 1113 cases from the Israeli CLL Study Group.Eur. J. Haematol., 2014; 93: 29-33
  Google Scholar
• 36. Slager S.L., Benavente Y., Blair A., Vermeulen R., Cerhan J.R.,Costantini A.S., Monnereau A., Nieters A., Clavel J., Call T.G., MaynadiéM., Lan Q., Clarke C.A., Lightfoot T., Norman A.D., SampsonJ.N., Casabonne D., Cocco P., de Sanjosé S.: Medical history, lifestyle,family history, and occupational risk factors for chronic lymphocyticleukemia/small lymphocytic lymphoma: the InterLymph Non–hodgkin Lymphoma Subtypes Project. J. Natl. Cancer Inst. Monogr.,2014; 2014: 41-51
  Google Scholar
• 37. Srivastava A., Henneke P., Visintin A., Morse S.C., Martin V.,Watkins C., Paton J.C., Wessels M.R., Golenbock D.T., Malley R.: Theapoptotic response to pneumolysin is Toll-like receptor 4 dependentand protects against pneumococcal disease. Infect. Immun.,2005; 73: 6479-6487
  Google Scholar
• 38. Starska K., Głowacka E., Kulig A., Lewy-Trenda I., Bryś M., LewkowiczP.: The role of tumor cells in the modification of T lymphocytesactivity – the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cellsin squamous cell laryngeal carcinoma. Folia Histochem. Cytobiol.,2011; 49: 579-592
  Google Scholar
• 39. Szulc-Dąbrowska L., Gieryńska M., Depczyńska D., SchollenbergerA., Toka F.N.: Th17 lymphocytes in bacterial infections. PostępyHig. Med. Dośw., 2015; 69: 398-417
  Google Scholar
• 40. Tomlinson G., Chimalapati S., Pollard T., Lapp T., Cohen J., CamberleinE., Stafford S., Periselneris J., Aldridge C., Vollmer W., PicardC., Casanova J.L., Noursadeghi M., Brown J.: TLR-mediated inflammatoryresponses to Streptococcus pneumoniae are highly dependenton surface expression of bacterial lipoproteins. J. Immunol., 2014;193: 3736-3745
  Google Scholar
• 41. Voo K.S., Bover L., Harline M.L., Weng J., Sugimoto N., Liu Y.J.:Targeting of TLRs inhibits CD4+ regulatory T cell function and activateslymphocytes in human peripheral blood mononuclear cells.J. Immunol., 2014; 193: 627-634
  Google Scholar
• 42. Whitaker J.A., Shanafelt T.D., Poland G.A., Kay N.E.: Room forimprovement: immunizations for patients with monoclonal B-cell lymphocytosis or chronic lymphocytic leukemia. Clin. Adv. Hematol.Oncol., 2014; 12: 440-450
  Google Scholar
• 43. Własiuk P., Tomczak W., Zając M., Dmoszyńska A., GiannopoulosK.: Total expression of HLA-G and TLR-9 in chronic lymphocytic leukemiapatients. Hum. Immunol., 2013; 74: 1592-1597
  Google Scholar
• 44. Wolska A., Cebula-Obrzut B., Smolewski P., Robak T.: Effects ofToll-like receptor 7 and Toll-like receptor 9 signaling stimulators andinhibitors on chronic lymphocytic leukemia cells ex vivo and theirinteractions with cladribine. Leuk. Lymphoma, 2013; 54: 1268-1278
  Google Scholar
• 45. Ziolkowska E., Wolowiec D., Cebula-Obrzut B., Blonski J.Z., SmolewskiP., Robak T., Korycka-Wolowiec A.: Cytotoxic and apoptosis–inducing effects of bendamustine used alone and in combinationwith rituximab on chronic lymphocytic leukemia cells in vitro. PostępyHig. Med. Dośw, 2014; 68: 1433-1443
  Google Scholar

Pełna treść artykułu